All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
AACR 2017: Poster 3311/14 – Impact of autophagy alterations in AML
On Tuesday 4th April, at the 107th American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, there was a poster session focused on “Autophagy and Cancer”. During this session, a poster (3311/14) titled “The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up” by Giovanni Marconi from the Institute of Hematology, Bologna, Italy and colleagues was on display.
Marconi et al. aimed to clarify the role of autophagy and its impact in therapy response and survival outcomes in 148 newly diagnosed Acute Myeloid Leukemia (AML) patients (median age = 56 years) treated with induction chemotherapy regimens. Patients were divided into 3 groups based on alterations in gene pathways; group 1 (autophagy gene alterations), group 2 (AMP-activated Protein Kinase [AMPK] pathway gene alterations) and group 3 (alterations in genes involved in the switch from a physiological role of autophagy to a resiliency mechanism).
The key results were:
- Alterations in group 1 were associated with lower Complete Remission (CR) % after induction; P < 0.001
- Alterations in group 1 significantly led to a worse Overall Survival (OS, P < 0.001) and was associated with complex karyotype and TP53 mutations (P < 0.001)
- Significant differences were observed in terms of survival independently both in gain and loss in group 1 genes, P < 0.001
- Alterations in group 2 and group 3 were associated with worse OS; P < 0.001
- Alterations in group 2 and group 3 were associated with lower CR % after induction; P < 0.001
The authors highlighted that their study is the first to use a “genomic approach” to identify the role of autophagy in AML. They further concluded by stating that “gain and loss in autophagy key regulator genes are associated with poor prognosis and therapy resistance” in AML.
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?